Safety & evidence

GHK-Cu
side effects

What studies, a cosmetic safety panel and regulators have recorded about GHK-Cu side effects, split by how it is used: on the skin in cosmetics, or injected. Dated 18 November 2026.

Short answerSafety & evidence · 6 min read · Updated 18 Nov 2026

Little is recorded about GHK-Cu side effects. For skin care, an industry-funded US cosmetic panel found in 2018 that low use concentrations and negative safety tests set aside concerns about copper tripeptide-1, GHK-Cu’s cosmetic name, and we found no published case report of a reaction. For injected GHK-Cu we found no controlled study; FDA cites “limited data in humans” and a possible immune-reaction risk.

Key takeaways

  • The human studies of GHK-Cu we found applied it to the skin, and they were small and short.
  • In 2018 the US Cosmetic Ingredient Review panel, funded by the cosmetics industry’s trade association, found no safety concern for copper tripeptide-1 at the low concentrations used in cosmetics. Its conclusion covers cosmetic use only, not injected GHK-Cu.
  • We found no published case report of a skin reaction to GHK-Cu (PubMed, 18 Nov 2026); a 2026 review notes that copper is a recognised contact sensitiser in susceptible people.
  • For injected GHK-Cu, FDA says compounded products may pose a risk of immune reactions from aggregation and impurities, with limited human data; we found no controlled trial.
  • Australia’s TGA names GHK-Cu among unapproved peptide products “often supplied in injectable form”, and lists their side effects and contents as unknown.

01GHK-Cu side effects at a glance

What is recorded, by how GHK-Cu is used, dated 18 November 2026.

QuestionOn the skin (cosmetics)Injected
Human studiesSmall, short cosmetic studies, mostly conference reports; one PubMed-indexed randomised trial, with 13 completersNo controlled trial found, published or registered (18 Nov 2026)
Recorded side effects in peopleNo published case report of a reaction found (PubMed, 18 Nov 2026); a 2026 review reports no serious adverse events in an 18-person eyebrow studyFDA: “limited data in humans to inform safety-related considerations”
Expert or regulator viewCosmetic Ingredient Review panel, 2018: no safety concern for copper tripeptide-1 at the low concentrations used in cosmetics. Industry-funded; not a regulatorFDA: compounded injectable GHK-Cu “may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities”
AustraliaWe have not verified how Australian rules treat a cosmetic containing itThe TGA names GHK-Cu among unapproved peptide products, “often supplied in injectable form”, whose side effects it lists as unknown
Laboratory dataHuman skin cells, 2016: no change in irritation markers at the concentrations tested, unlike two copper salts (T4)Not covered by the sources on this page
Concerns raised in a 2026 reviewCopper is “a recognized contact sensitizer in susceptible individuals”; cumulative copper burden with chronic or large-area use“Cumulative copper burden” with repeated injection; metal-allergy screening warranted for injectable products
Long-term safetyUnknown: the studies were small and shortUnknown: we found no published long-term human study

02What side effects are recorded for GHK-Cu on the skin?

The skin-care record is thin: small studies, an industry-funded panel review, and no published case report of a reaction that we could find.

Human studies. The skin studies of GHK-Cu are small and short; most were conference posters or pilot reports, known through a 2018 review by GHK’s discoverer. The one PubMed-indexed randomised trial of a skin-care regimen had 13 completers. A 2026 review reports that a 12-week study of a GHK-Cu serum on the eyebrows of 18 healthy adults recorded no serious adverse events. Both halves matter: studies this size can show that common, immediate problems were not obvious, but not that uncommon or delayed reactions never happen. The studies themselves: topical GHK-Cu.

Case reports. We found no published case report of a skin reaction to GHK-Cu or another copper peptide (PubMed, 18 November 2026). That means none was written up in the journals PubMed indexes, not that none has happened.

A cosmetic safety panel. In 2018 the US Cosmetic Ingredient Review (CIR) Expert Panel assessed tripeptide-1 (GHK), its metal salts and related ingredients, and noted that copper tripeptide-1 is used in cosmetic products. It wrote that “the low use concentrations and negative safety test data reviewed obviate any concerns relating to the safety of these ingredients in cosmetic products”, a conclusion it limited to “the present practices of use and concentration described in this safety assessment”, in which typical use concentrations were in the parts-per-million range. The conclusion covers cosmetic use only. CIR is not a regulator: the cosmetics industry’s trade association, now the Personal Care Products Council, set it up in 1976 and funds it, and CIR describes its review process as independent. We read the panel’s published summary; the full report was not accessible to us. None of the opinions on the EU Scientific Committee on Consumer Safety’s current opinions page concerns copper tripeptide-1 (read 18 November 2026).

Laboratory data. In a 2016 study of human skin cells by researchers at the National University of Singapore and 3M, GHK-Cu did not reduce cell viability or change skin-irritation markers at the concentrations tested, while copper chloride and copper acetate raised several of them. A cell model is not a person (T4).

The caution. A 2026 review in Pharmaceutics, whose authors declare no conflicts of interest, notes that copper “is a recognized contact sensitizer in susceptible individuals”, and that skin products need irritation, sensitisation and phototoxicity testing with attention to copper. That is a caution about copper, not a recorded reaction to GHK-Cu.

03What is known about injected GHK-Cu side effects?

We found no controlled study in people. What exists are regulator warnings, a few adverse-event reports that list it among other products, and gaps.

FDA. FDA’s compounding page lists “GHK-Cu (for injectable routes of administration)” among substances previously in Category 2, the category for bulk substances that may present significant safety risks, whose nominations were withdrawn by the nominators (page current 22 April 2026). Its entry says compounded injectable drugs containing GHK-Cu “may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities”, immunogenicity being the tendency to provoke an immune response, and that “there are limited data in humans to inform safety-related considerations”.

Australia. The TGA’s April 2026 safety advisory names GHK-Cu, with BPC-157, TB-500, retatrutide and CJC-1295, among examples of unapproved peptide products, “often supplied in injectable form”. It says these products “have not been assessed by the TGA for safety, quality or effectiveness”, that unknowns include “what side effects they may cause, and what substances these products actually contain”, and that unapproved peptide products, “particularly those that are injected, can carry other significant safety risks, including contamination, infection or local tissue damage”. The TGA lists adverse events it has received for unapproved peptide products, including severe allergic reactions requiring adrenaline and hospitalisation, without saying which products were involved. We read the advisory on the Internet Archive capture of 10 August 2026, because tga.gov.au did not respond. Victoria’s Chief Health Officer reported 13 anaphylaxis cases associated with unapproved peptides notified since July 2025 (advisory of 27 October 2026); the advisory names no substance.

FDA’s adverse-event database. FDA’s public adverse-event data (FAERS, since renamed the FDA Adverse Event Monitoring System; data to 28 October 2026) hold three reports that list a product named GHK-Cu or “copper tripeptide” among other products the person used. In each, the reporter named a different product as the suspect: sermorelin acetate in a 2025 report coded as “anaphylactic shock”, “syncope” and nine other terms, with hospitalisation; chorionic gonadotrophin and Ozempic (semaglutide), both prescription medicines, in a 2026 consumer report coded as “adverse drug reaction”, “malignant lymphoid neoplasm” and “product dispensed by unauthorised provider”, where the GHK-Cu product was labelled as a blend with BPC-157 and TB-500; and lidocaine in a 2018 report from Japan coded as “haemorrhage” and “pain”, where copper tripeptide was one of more than a dozen ingredients listed for hair loss. The reports do not record how the GHK-Cu products were used. FDA says a report gives “no certainty that the reported adverse event was due to the suspect product”, and it does not receive every report.

Studies. We found no controlled trial of injected GHK-Cu, published or registered, and no published long-term human study (PubMed and ClinicalTrials.gov, 18 November 2026). The 2026 Pharmaceutics review writes that injectable copper-peptide preparations supplied outside an approved marketing authorisation “sit outside any defined evidentiary or quality framework”, that metal-allergy screening is warranted for injectable products, and that “the dominant long-term concern is cumulative copper burden” from repeated or prolonged exposure.

Skin studies say nothing about injection: a different route and a different exposure. The overview: GHK-Cu research guide. What the blue colour of a GHK-Cu solution can and cannot tell you: why is GHK-Cu blue?

04Who records reactions to cosmetics with GHK-Cu?

United States. FDA says cosmetic products and ingredients, apart from colour additives, “do not require FDA approval before they go on the market”. Since the Modernization of Cosmetics Regulation Act of 2022, the company responsible for a cosmetic must report serious adverse events it receives to FDA within 15 business days. FDA says a product’s status “is determined by a product’s intended use”: one intended to affect the structure or any function of the body is a drug.

EU and Great Britain. Each cosmetic product needs a safety assessment before it goes on the market, whatever peptide it contains. More on these rules: peptides in skincare.

Reaction to any product? Seek medical care first, then report it: how to report a reaction in the US, UK or Australia. How to weigh reports like these: peptide side effects, documented and unknown.

05What we don’t know about GHK-Cu side effects

  • How often skin reactions to GHK-Cu products occur. The studies were small, and case reports cannot give a rate.
  • Whether injected GHK-Cu causes harm in people, and how often. We found no controlled human study, and FDA cites limited human data.
  • Long-term effects by any route, including copper exposure over months or years.
  • Whether a given reaction came from GHK-Cu, another ingredient, an impurity or the wrong substance. Only that lot’s lab report can show what a vial holds: how to read a COA.

For anything about your health, a doctor who knows you is the right call.

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not medical advice.

RefSources

  1. Johnson W Jr, Bergfeld WF, Belsito DV, et al. Safety assessment of tripeptide-1, hexapeptide-12, their metal salts and fatty acyl derivatives, and palmitoyl tetrapeptide-7 as used in cosmetics. Int J Toxicol, 2018;37(3 suppl):90S–102S. doi 10.1177/1091581818807863 (abstract read 18 Nov 2026; full text not accessible to us). doi.org/10.1177/1091581818807863
  2. Cosmetic Ingredient Review. About CIR. Web page, read 18 Nov 2026. www.cir-safety.org/about
  3. European Commission. Scientific Committee on Consumer Safety (SCCS): opinions. Web page, read 18 Nov 2026. health.ec.europa.eu/scientific-committees/scientific-committ…
  4. Mateescu DM, Gavrilescu DM, Mincioaga RI, et al. [Evidence-map review of GHK-Cu chemistry, formulation, evidence and safety requirements]. Pharmaceutics, 2026;18(9):1077. PMID 42797253 (full text read 18 Nov 2026). pmc.ncbi.nlm.nih.gov/articles/PMC13610439/
  5. Li H, Toh PZ, Tan JY, et al. Selected biomarkers revealed potential skin toxicity caused by certain copper compounds. Sci Rep, 2016;6:37664. PMID 27892491. pubmed.ncbi.nlm.nih.gov/27892491/
  6. Pickart L, Margolina A. [Review of GHK-Cu research, including summaries of small skin studies, by GHK’s discoverer]. Int J Mol Sci, 2018;19(7):1987. PMID 29986520. pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
  7. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 2006;8(4):252–259. PMID 16847171. pubmed.ncbi.nlm.nih.gov/16847171/
  8. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Web page, content current as of 22 Apr 2026; read 18 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  9. Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 Apr 2026; read on the Internet Archive capture of 10 Aug 2026, the newest capture, because tga.gov.au did not respond on 18 Nov 2026. www.tga.gov.au/safety/safety-monitoring-and-information/safe…
  10. Department of Health, Victoria. Increase in anaphylaxis notifications related to unapproved peptides in Victoria. Health advisory 261027, 27 Oct 2026; read 18 Nov 2026. www.health.vic.gov.au/health-advisories/anaphylaxis-notifica…
  11. U.S. Food and Drug Administration. Is it a cosmetic, a drug, or both? (Or is it soap?) and Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Web pages, content current as of 11 Sep 2024 and 29 Oct 2026; read 18 Nov 2026. www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic…
  12. Regulation (EC) No 1223/2009 on cosmetic products, Article 10 (safety assessment); in Great Britain as amended, per the Office for Product Safety and Standards. EUR-Lex text and GOV.UK guidance, read 18 Nov 2026. eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32009R1223
  13. PubMed and ClinicalTrials.gov searches run 18 Nov 2026: copper peptide terms (GHK-Cu, copper peptide, copper tripeptide, prezatide, AHK-Cu) with safety terms (16 records, none a case report) and with the case-report publication type (none); “uglies” (2 unrelated records); ClinicalTrials.gov “GHK-Cu” and “copper tripeptide-1” (no study of injected GHK-Cu). Database searches. pubmed.ncbi.nlm.nih.gov/?term=%28%22GHK-Cu%22%5Btiab%5D+OR+%…
  14. U.S. Food and Drug Administration. openFDA drug adverse event API (FAERS public data, last updated 28 Oct 2026): products named GHK* or “copper tripeptide”, 3 reports (25484639, 26810736, 15328259), each listing it as a concomitant product. The caveat on causality is quoted from FDA’s briefing document on BPC-157 for the July 2026 compounding advisory committee meeting (p. 41). Database query, run 18 Nov 2026; briefing re-read 18 Nov 2026. api.fda.gov/drug/event.json?search=patient.drug.medicinalpro…

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

What are the side effects of GHK-Cu?

Little is recorded. For skin care, an industry-funded US cosmetic safety panel found in 2018 no safety concern at the low concentrations used in cosmetics, and we found no published case report of a reaction. For injected GHK-Cu, FDA cites limited human data and a possible risk of immune reactions, and we found no controlled study.

Can GHK-Cu cause an allergic reaction?

We found no published case report of an allergic reaction to GHK-Cu. One report in FDA’s adverse-event database describes anaphylactic shock in a person using sermorelin, with GHK-Cu and BPC-157 listed as other products; the reporter named sermorelin as the suspect, and a report does not show what caused an event. A 2026 review notes that copper is a recognised contact sensitiser in susceptible people, and Australia’s TGA has received reports of severe allergic reactions to unapproved peptide products without saying which products were involved.

Do skin-care findings apply to injected GHK-Cu?

No. The human studies applied it to the skin. FDA says there are limited human data on injectable GHK-Cu, and we found no controlled trial of it.

Is there research on “GHK-Cu uglies”?

We found no study, case report or regulator document that uses the phrase (PubMed and the documents cited here, 18 Nov 2026). Posts online are not adverse-event data; a suspected reaction should be reported to a regulator.

How do I report a reaction to a GHK-Cu product?

Seek medical care first. Then report it to FDA MedWatch in the US, the MHRA Yellow Card scheme in the UK or the TGA in Australia; our reporting page explains each route.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page